Navigation Links
Increased risk of relapse omitting RT in early PET scan negative Hodgkin lymphoma
Date:3/19/2014

Interim analysis of the intergroup EORTC-LYSA-FIL 20051 H10 trial published in the Journal of Clinical Oncology indicates an increased risk of early relapse when omitting radiotherapy in early PET scan negative patients with stage I/II Hodgkin's lymphoma. Early outcome, however, was excellent in both arms, and the final analysis should reveal whether these initial findings are maintained over time.

Dr. J.M.M. Raemaekers of the Radboud university medical center Nijmegen, The Netherlands, and central coordinator of the study says, "The standard treatment for patients with clinical stage I/II Hodgkin's Lymphoma is ABVD (adriamycin, bleomycin, vinblastin and dacarbazin) chemotherapy followed by radiotherapy. Striking the right balance between initial cure through combined modality treatment and accepting a higher risk of late complications, and a higher recurrence rate after omitting radiotherapy in subsets of patients who will subsequently need intensive salvage treatment, is a matter of unsettled debate."

The main objective of the H10 trial was to evaluate whether involved-node radiotherapy could be omitted without loss of efficacy in terms of progression-free survival in patients with stage I/II Hodgkin's Lymphoma who had a negative earlyPET scan after two cycles of ABVD chemotherapy. This interim trial analysis included a total of 1137 patients with untreated clinical stage I/II Hodgkin's Lymphoma. Of these, 444 patients had favorable and 693 unfavorable prognoses. Patients in each prognostic group were randomized between standard and experimental treatment and first received two cycles of ABVD chemotherapy. Patients in the experimental arm who attained a negative earlyPET scan after the two cycles of ABVD chemotherapy were spared involved-node radiotherapy.

For patients with a favorable prognosis and a negative earlyPET scan, one progression occurred in the standard arm and nine progressions occurred in the experimental arm. For patients with unfavorable prognosis and a negative earlyPET scan, seven events occurred in the standard arm and 16 events occurred in the experimental arm. Even though there were few events and the median follow-up time short, the Independent Data Monitoring Committee concluded it was unlikely that the final results would show non-inferiority for the experimental treatment. They, therefore, advised that randomization should be stopped for earlyPET negative patients.


'/>"/>

Contact: John Bean
john.bean@eortc.be
European Organisation for Research and Treatment of Cancer
Source:Eurekalert

Related medicine news :

1. Gestational diabetes linked to increased risk for heart disease in midlife
2. Despite recession, childrens health spending increased between 2009-2012, says new report
3. Death of partner associated with increased risk of heart attack, stroke
4. Smoking linked with increased risk of most common type of breast cancer
5. New clues may link hereditary cancer genes to increased risk of cancer from alcohol
6. Patients with multiple sclerosis in Taiwan may be at increased risk of developing cancer
7. Increased risk of prostate cancer in African-American men; implications for PSA screening
8. No brakes -- Study finds mechanism for increased activity of oncogene in certain cancers
9. Hospital-diagnosed maternal infections linked to increased autism risk
10. Local Campaign to Educate African American Women on Increased Risk of Breast Cancer
11. In Light of Increased Levels of Personal Stress Over the Holiday Season, Lanahan Insurance Recommends Staying Covered with Health Insurance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... ... , ... The homeowner improvement and repair market is expected to reach $317 ... for renovations is also on the rise. Per a 2017 report, 13% of all ... failed to use a licensed contractor.(2) The risks associated with improper renovations—especially tiling—can not ...
(Date:3/26/2017)... Columbus, Ohio (PRWEB) , ... March 26, 2017 ... ... 100 doctors worldwide to receive the RealSelf 100 Award, a prestigious award honoring ... elective cosmetic procedures and to find and connect with doctors and clinics. , ...
(Date:3/25/2017)... ... ... at Swissray is pleased to announce the release of the ELITE DXA, a new ... active scan window, which is more than double that of existing bone densitometers. Historically, ... undergo an accurate total body bone density or body composition study. The ELITE ...
(Date:3/24/2017)... ... 24, 2017 , ... Vighter established its NAEMT Authorized Training ... Prehospital Trauma Life Support (PHTLS) course scholarships to four medics assigned to the ... in cooperation with the American College of Surgeons to promote critical thinking in ...
(Date:3/24/2017)... ... March 24, 2017 , ... Infectious ... to hospitals in the United States, it’s a threat that is constantly changing ... facing infection prevention and offers strategies for the healthcare community to help decrease ...
Breaking Medicine News(10 mins):
(Date:3/27/2017)... BOSTON , March 27, 2017 /PRNewswire/ ... company and Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a ... of innovative therapies based upon tetracycline chemistry, announced ... for the treatment of moderate to severe acne ... is a once-daily, oral, narrow spectrum tetracycline-derived antibiotic ...
(Date:3/27/2017)... -- Impax Laboratories, Inc. (NASDAQ: IPXL)today announced that its Board ... as Impax,s President and Chief Executive Officer and a ... Mr. Bisaro will succeed J. Kevin Buchi , ... Officer since December of 2016. With ... Bisaro, 56, is an accomplished global business leader who ...
(Date:3/27/2017)... , March 27, 2017  PhaseRx, Inc. ... for life-threatening inherited liver diseases in children, today ... full year ended December 31, 2016 and provided ... "PhaseRx continued to make progress during the ... positive results from our non-human primate safety study, and ...
Breaking Medicine Technology: